SensiVida Medical Technologies (PINKSHEETS: SVMT), a developer and provider of painless diagnostic technologies, announced today that it exhibited its Digital Allergy Test System at the 2010 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting in Phoenix, Arizona earlier this month.

"This was the first time we introduced our Digital Allergy Test System to the allergist community and we were overwhelmed by the positive feedback we received," said Dr. Scott Rosebrough, SensiVida's Director of Preclinical and Clinical Development. "Many of the allergists said that it was one of the most innovative developments at the conference and that they would adopt the product as soon as it received FDA market clearance."

The SensiVida Digital Allergy Test System employs a compact one-time use cartridge preloaded with 40 different allergens and ultra-fine microneedles. The allergens are painlessly delivered to the skin in a single, rapid motion. A digital imaging system supported with proprietary image processing technology captures images of the reaction site in real-time and transfers them to a computer for analysis. Digital reports are automatically created which can be printed or loaded into electronic medical records.

In addition to the positive response received by allergists, SensiVida received extremely positive feedback from a number of allergy and immunology industry participants, regulatory groups and potential business partners.

About The American College of Allergy, Asthma and Immunology

The American College of Allergy, Asthma and Immunology, established in 1942, is a professional association of more than 5,000 allergists/immunologists and allied health professionals. Its mission is to promote excellence in the practice of the subspecialty of allergy and immunology. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. More information about ACAAI can be found on their website at www.acaai.org

SensiVida has an exclusive worldwide license to nine pending patents. In addition to the SensiVida allergy test, the product pipeline, based on the same microsystem and image processing technology, includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient's test schedule, automatically recording the patient's glucose level without pain, bio-fouling or clogging. For more information about SensiVida, please visit www.sensividamedical.com or www.sensividamedical.wordpress.com.

Forward-Looking Statements:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Quarterly Report on Form 10Q and related 8-K filings.